Skip to main content
Article
Response to interferon-beta treatment in multiple sclerosis patients: A genome-wide association study.
The Pharmacogenomics Journal
  • S Mahurkar, University of South Australia
  • M Moldovan, University of South Australia
  • V Suppiah, University of South Australia
  • M Sorosina, San Raffaele Scientific Institute, Milan, Italy
  • F Clarelli, San Raffaele Scientific Institute, Milan, Italy
  • G Liberatore, San Raffaele Scientific Institute, Milan, Italy
  • S Malhotra, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • X Montalban, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • A Antigüedad, Servicio de Neurología, Basurto Hospital, Bilbao, Spain
  • M Krupa, Flinders University and Medical Centre, Adelaide
  • V G Jokubaitis, The University of Melbourne
  • F C McKay, University of Sydney
  • P N Gatt, University of Sydney
  • M J Fabis-Pedrini, University of Western Australia
  • V Martinelli, San Raffaele Scientific Institute, Milan, Italy
  • G Comi, San Raffaele Scientific Institute, Milan, Italy
  • J Lechner-Scott, The University of Newcastle, New South Wales
  • A G Kermode, University of Western Australia
  • M Slee, Flinders University and Medical Centre, Adelaide
  • B V Taylor, University of Tasmania, Australia
  • K Vandenbroeck, Neurogenomiks Group, Universidad del País Vasco (UPV/EHU), Leioa, Spain
  • M Comabella, Universitat Autònoma de Barcelona, Barcelona, Spain
  • F M Boneschi, San Raffaele Scientific Institute, Milan, Italy
  • ANZgene consortium inc Lotti Tajouri (Bond University)
  • C King, University of South Australia
Date of this Version
3-22-2016
Document Type
Journal Article
Publication Details

Citation only

Mahurkar, S., Moldovan, M., Suppiah, V., Sorosina, M., Clarelli, F., Liberatore, G., Malhotra, S., Montalban, X., Antigüedad, A., Krupa, M., Jokubaitis, V.G., McKay, F.C., Gatt, P.N., Fabis-Pedrini, M.J., Martinelli, V., Comi,G., Lechner-Scott, J., Kermode, A.G., Slee, M., Taylor, B.V., Vandenbroeck, K., Comabella, M., Boneschi, F.M., ANZgene consortium inc Lotti Tajouri, King C. (2016, in press). Response to interferon-beta treatment in multiple sclerosis patients: A genome-wide association study. The Pharmacogenomics Journal.

Access the journal

Copyright © 2016, Nature Publishing Group. All rights reserved.

Abstract

Up to 50% of multiple sclerosis (MS) patients do not respond to interferon-beta (IFN-β) treatment and determination of response requires lengthy clinical follow-up of up to 2 years. Response predictive genetic markers would significantly improve disease management. We aimed to identify IFN-β treatment response genetic marker(s) by performing a two-stage genome-wide association study (GWAS). The GWAS was carried out using data from 151 Australian MS patients from the ANZgene/WTCCC2 MS susceptibility GWAS (responder (R)=51, intermediate responders=24 and non-responders (NR)=76). Of the single-nucleotide polymorphisms (SNP) that were validated in an independent group of 479 IFN-β-treated MS patients from Australia, Spain and Italy (R=273 and NR=206), eight showed evidence of association with treatment response. Among the replicated associations, the strongest was observed for FHIT (Fragile Histidine Triad; combined P-value 6.74 × 10(-)(6)) and followed by variants in GAPVD1 (GTPase activating protein and VPS9 domains 1; combined P-value 5.83 × 10(-5)) and near ZNF697 (combined P-value 8.15 × 10(-5)).

Citation Information
S Mahurkar, M Moldovan, V Suppiah, M Sorosina, et al.. "Response to interferon-beta treatment in multiple sclerosis patients: A genome-wide association study." The Pharmacogenomics Journal (2016) ISSN: 1473-1150
Available at: http://works.bepress.com/lotti_tajouri/40/